Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Docusign Inc (DOCU) vs Morgan Stanley (MS) Price & Performance

Docusign IncTrade
Morgan StanleyTrade

Price performance (Past 24H)

Key statistics

Docusign Inc vs Morgan Stanley — how do they compare? Docusign Inc trades at $71.49 (market cap $13.35B), while Morgan Stanley trades at $189.1 (market cap $294.39B). The key difference: Morgan Stanley is far larger — about 22.1× Docusign Inc's market cap, and Morgan Stanley pays a 2.45% dividend while Docusign Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Docusign Inc for 71 Days and Morgan Stanley for 93 Days on average.

DOCUMS
Market Cap
$13.35B$294.39B
Volume
3,158,8585,836,423
Sector
TechnologyFinancials
52-Week High
$73.14$228.42
52-Week Low
$41.75$151.86
Typical Hold Time
71 Days93 Days
Enterprise Value
$12.76B$660.04B
Dividend Yield
—2.45%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Docusign Inc

DocuSign (DOCU) trades at $68.9, up 1.0% on the day, with a bullish technical outlook supported by moving averages. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $1.16 surpassing the $1.09 forecast. Revenue growth remains solid, reaching $2.98B in 2025, while profitability has improved significantly, with net income margin at 9.82%. Recent news highlights strong momentum, including a 50.8% stock surge over three months and leadership in IDC's integrated signing workflow software assessment (IDC MarketScape, August 2026).

The outlook for DOCU is cautiously optimistic, driven by AI-powered Intelligent Agreement Management adoption and operating leverage. However, risks include saturation in the e-signature market, insider selling activity, and a high P/E ratio of 42.01. Analyst consensus is mixed, with a Hold rating predominating (64.29%) and a price target of $68.75, slightly below the current price. Investors should weigh strong cash flow generation against valuation concerns and competitive pressures.

Morgan Stanley

Morgan Stanley (MS) trades at $189.71, down 0.66% with bearish technical signals despite strong fundamentals. The company has delivered three consecutive earnings beats with Q2 2026 EPS of $3.46 beating expectations by $0.57. Revenue growth accelerated to $66.0 billion in 2025 with net income margin expanding to 27.59%. Analyst consensus remains bullish with 55.77% buy ratings and a $229.25 price target representing 21% upside potential.

The investment case balances strong profitability and growth opportunities in wealth management and AI financing against concerning cash flow trends and technical weakness. While valuation appears reasonable at 15.14 P/E, investors face risks from volatile operating cash flows and rising debt levels. The stock offers attractive upside to analyst targets but requires monitoring of capital markets recovery timing.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

DOCU
0% Buy100% Sell
Avg holding period · 71 Days
MS
100% Buy0% Sell
Avg holding period · 93 Days

Top news

Latest headlines on both assets

About Docusign Inc

DocuSign offers the Agreement Cloud, a broad cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device. The company was founded in 2003 and completed its IPO in May 2018.

Read more on DOCU →

About Morgan Stanley

Morgan Stanley is a global investment bank whose history, through its legacy firms, can be traced back to 1924. The company has institutional securities, wealth management, and investment management segments. The company had about $5 trillion of client assets as well as over 70,000 employees at the end of 2021. Approximately 50% of the company's net revenue is from its institutional securities business, with the remainder coming from wealth and investment management. The company derives about 30% of its total revenue outside the Americas.

Read more on MS →